Replimune Group Inc (NAS:REPL)
$ 7.9 0.79 (11.11%) Market Cap: 485.18 Mil Enterprise Value: 91.86 Mil PE Ratio: 0 PB Ratio: 1.17 GF Score: 30/100

Replimune Group Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 01:00AM GMT
Release Date Price: $18.27 (+1.61%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Start?

Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer

Yes.

Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. So welcome to the Tuesday afternoon session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Replimune, and presenting on behalf of the company is CEO, Philip Astley-Sparke.

Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer

Thanks, Anupam. Safe harbor. So Replimune. Replimune was founded in 2015 to realize the full potential of oncolytic immunotherapy. We believe that our products become the second cornerstone of immuno-oncology. Our lead asset, RP1, primarily focuses on immuno-responsive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot